Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market

Alkermes plc (ALKS) announced an update on their ongoing clinical study.

The Brilliance NT2 Study 303 is a phase 3 trial from Alkermes, Inc. that tests ALKS 2680 in adults with narcolepsy type 2. It aims to see if the drug can cut daytime sleepiness and reduce core symptoms, which could open a new treatment option in a niche but growing sleep-disorder market.

The study tests ALKS 2680, also called Alixorexton, as a once-daily oral tablet. It is designed to boost wakefulness and ease narcolepsy type 2 symptoms, with three dose levels compared directly against a placebo.

This is a randomized study, so participants are assigned by chance to one of three ALKS 2680 doses or a placebo group. It is triple-blind, meaning patients, doctors, and study staff do not know who gets which treatment, and the main goal is to see if the drug works better than placebo for treatment.

The trial is interventional, with parallel groups followed over 12 weeks of daily dosing. This design is standard for late-stage drug testing and should give clear data on both benefit and safety across different doses.

The study was first submitted on Mar. 26, 2026, marking the formal start of regulatory tracking. The latest update on May 5, 2026, confirms the trial is active and still recruiting, which matters for timing of key readouts.

Primary completion and final completion dates are not yet posted, but investors can expect typical phase 3 timelines of one to three years from start. Any update that adds concrete dates will help the market tighten expectations around data and possible filing windows.

For Alkermes (ALKS), positive results here could support a new growth driver beyond its current neuroscience and psychiatry portfolio. A once-daily narcolepsy pill with solid data could lift long-term revenue forecasts and improve sentiment toward the pipeline.

The narcolepsy field already includes players like Jazz Pharmaceuticals with Xyrem and Xywav, and emerging orexin-focused drugs from competitors. A strong phase 3 showing for ALKS 2680 could position Alkermes as a credible contender and may spark re-rating across sleep-disorder names.

Near term, the main trading impact is likely to be sentiment-driven as investors track enrollment and future milestone dates. Volatility could rise closer to data readouts, with both upside and downside risk tied to how well ALKS 2680 stacks up against existing standards.

The Brilliance NT2 Study 303 is currently recruiting and recently updated, and further details remain available on the ClinicalTrials portal.

To learn more about ALKS’s potential, visit the Alkermes plc drug pipeline page.